These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11518088)

  • 1. Drug-intake regulation and the interplay between economic costs and benefits: comment on Lynch and Carroll (2001).
    Madden GJ
    Exp Clin Psychopharmacol; 2001 May; 9(2):148-50; discussion 160-2. PubMed ID: 11518088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No thanks, I'm good. Any more and I'll be sick: comment on Lynch and Carroll (2001).
    Killeen PR; Reilly MP
    Exp Clin Psychopharmacol; 2001 May; 9(2):144-7; discussion 160-2. PubMed ID: 11518087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How does regulation of drug intake come about? Comment on Lynch and Carroll (2001).
    Woods JH
    Exp Clin Psychopharmacol; 2001 May; 9(2):155-6; discussion 160-2. PubMed ID: 11518090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Satiety threshold regulates maintained self-administration: comment on Lynch and Carroll (2001).
    Norman AB; Tsibulsky VL
    Exp Clin Psychopharmacol; 2001 May; 9(2):151-4; discussion 160-2. PubMed ID: 11518089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of drug intake.
    Lynch WJ; Carroll ME
    Exp Clin Psychopharmacol; 2001 May; 9(2):131-43. PubMed ID: 11518086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access conditions are crucial: comment on Lynch and Carroll (2001).
    Young AM
    Exp Clin Psychopharmacol; 2001 May; 9(2):157-9; discussion 160-2. PubMed ID: 11518091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of pharmacoeconomics in prescribing research. Part 1: costs--moving beyond the acquisition price for drugs.
    Robertson J; Lang D; Hill S
    J Clin Pharm Ther; 2003 Feb; 28(1):73-9. PubMed ID: 12605622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of pharmacoeconomic studies of pharmacogenomic tests.
    Beaulieu M; de Denus S; Lachaine J
    Pharmacogenomics; 2010 Nov; 11(11):1573-90. PubMed ID: 21121811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug therapy: safety, effectiveness, and economics.
    Brandys J
    Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Counting the costs of drug-related adverse events.
    White TJ; Arakelian A; Rho JP
    Pharmacoeconomics; 1999 May; 15(5):445-58. PubMed ID: 10537962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic costs of adverse drug reactions.
    Dukes MN
    Pharmacoeconomics; 1992 Mar; 1(3):153-4. PubMed ID: 10172055
    [No Abstract]   [Full Text] [Related]  

  • 12. [Validation of parenteral drug production: benefits and costs].
    Tagliapietra L
    Boll Chim Farm; 1985 Jul; 124(7):285-92. PubMed ID: 3935136
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the economic impact of adverse drug effects.
    Rodríguez-Monguió R; Otero MJ; Rovira J
    Pharmacoeconomics; 2003; 21(9):623-50. PubMed ID: 12807365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using benefit harm tradeoffs to estimate sufficiently important difference: the case of the common cold.
    Barrett B; Brown R; Mundt M; Dye L; Alt J; Safdar N; Maberry R
    Med Decis Making; 2005; 25(1):47-55. PubMed ID: 15673581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics.
    Garattini L; Grilli R; Scopelliti D; Mantovani L
    Pharmacoeconomics; 1995 Jan; 7(1):1-6. PubMed ID: 10155289
    [No Abstract]   [Full Text] [Related]  

  • 16. Protocol-driven costs in trial-based pharmacoeconomic analyses.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):673-5. PubMed ID: 22098282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carroll's Three-Stratum (3S) Cognitive Ability Theory at 30 Years: Impact, 3S-CHC Theory Clarification, Structural Replication, and Cognitive-Achievement Psychometric Network Analysis Extension.
    McGrew KS
    J Intell; 2023 Feb; 11(2):. PubMed ID: 36826930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological approaches to pharmaco-economics.
    Souêtre EJ; Qing W; Hardens M
    Fundam Clin Pharmacol; 1994; 8(2):101-7. PubMed ID: 8020868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of noncontingent reinforcement on problem behavior and stimulus engagement: the role of satiation, extinction, and alternative reinforcement.
    Hagopian LP; Crockett JL; van Stone M; DeLeon IG; Bowman LG
    J Appl Behav Anal; 2000; 33(4):433-49. PubMed ID: 11214021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of importing prescription medications from lower-income countries.
    Dhalla IA; Detsky AS
    JAMA; 2008 Sep; 300(12):1453-5. PubMed ID: 18812537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.